STOCK TITAN

AbCellera to Report Third Quarter 2021 Financial Results on November 9, 2021

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) will announce its third quarter 2021 financial results on Tuesday, November 9, 2021, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

The live webcast of the earnings conference will be available through a link that will be posted on AbCellera’s Investor Relations website. A replay of the webcast will be available through the same link following the conference call.

About AbCellera Biologics Inc.

AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. To learn more, visit www.abcellera.com.

Source: AbCellera Biologics Inc.

Media: Jessica Yingling, Ph.D.; media@abcellera.com, +1(236)521-6774

Investor Relations: Melanie Solomon; ir@abcellera.com, +1(778)729-9116

Source: AbCellera Biologics Inc.

AbCellera Biologics Inc

NASDAQ:ABCL

ABCL Rankings

ABCL Latest News

ABCL Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
CA
Vancouver

About ABCL

abcellera is a canadian biotechnology company focused on accelerating the discovery of monoclonal antibody (mabs) therapeutics. antibodies are molecules that are naturally produced by the immune system of humans or animals to fight off infection and disease. the unique property of antibodies is that they can specifically recognize and target diseased cells or pathogens, making them precise and highly effective drugs with low side effects for the treatment of cancer, autoimmune disorders and infections. the immune system is capable of making billions to trillions of unique antibodies, each produced by a single immune cell. of these, only a select few are suitable for therapeutic applications. finding these rare antibodies presents a major roadblock in the development of new therapeutics. abcellera addresses this bottleneck by using microfluidic technology for the rapid and high-throughput analysis of antibodies directly from single cells. abcellera is a spinoff from dr. carl hansen’